St. Louis-based Precision Virologics and India’s Biotech leader Bharat Biotech obtain rights to intranasal COVID-19 vaccine technology (Links to an external site)

Biotech startup Precision Virologics, which develops adenovirus-based vaccines in St. Louis, and Bharat Biotech, a manufacturing giant of vaccines, jointly obtained rights from Washington University School of Medicine in St. Louis for a novel chimp-adenovirus vaccine for COVID-19. Precision Virologics has optioned rights for USA, Europe, and Japan. Bharat has obtained a license for all other markets.